MAVDA Projects and Cores

Metropolitan Anti-Viral Drug Accelerator (MAVDA), with its 5 projects and 7 cores, was created to engage world-class virologists and academic drug discovery experts, as well as industry professionals to accelerate the development of oral drugs against high-threat viruses of pandemic potential. MAVDA will serve as a robust platform for the development of innovative and selected Optimized Leads and Preclinical Development Candidates (PDC). In collaboration with our commercial partnerships, MAVDA will rapidly advance the most promising PDCs through the drug development matrix for downstream preclinical investigational new drug (IND) development.